Brief: Evelo Biosciences Announces Highly Significant Reductions In Clinically Validated Inflammatory Cytokines In EDP1815 Phase 2 Psoriasis Trial

Evelo Biosciences

07/02/2022 12:42

Feb 7 (Reuters) - Evelo Biosciences Inc  EVLO.O :
    * EVELO BIOSCIENCES ANNOUNCES HIGHLY SIGNIFICANT REDUCTIONS
IN
CLINICALLY VALIDATED INFLAMMATORY CYTOKINES IN EDP1815 PHASE 2
PSORIASIS TRIAL
    * EVELO BIOSCIENCES INC - TREATMENT WITH EDP1815 LED TO
REDUCED
PRODUCTION OF CYTOKINES IL-6, IL-8, AND TNF IN BLOOD CELLS
    * EVELO BIOSCIENCES INC - CYTOKINE ANALYSIS SUPPORTS
GUT-RESTRICTED ACTION OF EDP1815 TO RESOLVE INFLAMMATION
THROUGHOUT BODY
    * EVELO BIOSCIENCES INC - REDUCTIONS IN IL-12B, IL-17, AND
IL-23
IN SKIN LESIONS - ALL TARGETS OF APPROVED BIOLOGICS FOR
PSORIASIS
    * EVELO BIOSCIENCES INC - EXPECT TO START DOSING PATIENTS IN
PHASE
2 CLINICAL TRIAL IN ATOPIC DERMATITIS SOON

Source text for Eikon:  ID:nGNX3jJBPG 
Further company coverage:  EVLO.O 

 ((Reuters.Briefs@thomsonreuters.com;))